The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
SOHO 2024 live congress feed
Stay up to date with the latest developments in MPN from the SOHO 2024 Annual Meeting with our live social media coverage.
CONGRESS | #SOHO2024
— MPN_Hub (@MPN_Hub) September 5, 2024
Naseema Gangat, @MayoClinic, discusses accelerated and blast phase #MPN, focusing on diagnosis, risk factors for leukemic transformation, & role of allo-HSCT. She suggests early allo-HSCT for eligible patients once cytoreduction, lower blast % & spleen… pic.twitter.com/mNBzM6V03b
CONGRESS | #SOHO2024
— MPN_Hub (@MPN_Hub) September 5, 2024
Jason Gotlib @StanfordMed shares data from the phase II FIGHT-203 study of pemigatinib for myeloid/lymphoid neoplasms with FGFR1 rearrangement.
Median PFS and OS not reached, Grade ≥3 AEs 83%, CR rate 69%, ORR 78%, CCyR rate 71%.#MPN #MPNsm pic.twitter.com/Nk8eJE2SiM
CONGRESS | #SOHO2024
— MPN_Hub (@MPN_Hub) September 5, 2024
Roni Tamari @MSKCancerCenter provides and overview of who, when, and how to transplant patients with #myelofibrosis. Tamari emphasizes the consideration of disease-, and patient-related factors, as well as prognostic systems when determining who and when to… pic.twitter.com/uHyxJE7tZs
CONGRESS | #SOHO2024
— MPN_Hub (@MPN_Hub) September 5, 2024
Prithviraj Bose, @MDAndersonNews, discusses key data on available JAK inhibitors to help optimize their selection for treatment of #myelofibrosis. Generally, ruxolitinib and fedratinib are better suited for the myeloproliferative phenotype, while momelotinib… pic.twitter.com/p8850TO0Dg
CONGRESS | #SOHO2024@lauracmichaelis @MedicalCollege discusses the goals of therapy in #EssentialThrombocythemia and PolycythemiaVera.
— MPN_Hub (@MPN_Hub) September 5, 2024
Goals for both include managing venous and arterial thrombosis risk by correcting CV risk, providing appropriate anticoagulation, and… pic.twitter.com/hNauFIBqpI
CONGRESS | POSTER | #SOHO2024 |
— MPN_Hub (@MPN_Hub) September 5, 2024
Prithviraj Bose @bose_prithviraj presents 3-year follow-up data from the phase III PATHFINDER study of avapritinib in pts with advanced systemic #mastocytosis (N=107).
The ORR was 73% overall and 87% in treatment-naïve pts, with deep and sustained… pic.twitter.com/VadpwDccZG
CONGRESS | POSTER | #SOHO2024 |
— MPN_Hub (@MPN_Hub) September 4, 2024
John Mascarenhas @IcahnMountSinai presents the latest data from the phase III MANIFEST-2 study of pelabresib + ruxolitinib (N=214) vs placebo + ruxolitinib (N=216) in pts with JAKi-naïve #myelofibrosis.
The study met its primary endpoint, showing a… pic.twitter.com/ojnBr6SkA4
CONGRESS | POSTER | #SOHO2024 |
— MPN_Hub (@MPN_Hub) September 4, 2024
Tom Liu presents an exploratory post hoc analysis of the association between Hb improvements and PROs from a pooled analysis of momelotinib phase III SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM trails in patients with #myelofibrosis and anemia (N=480).… pic.twitter.com/zJP9kVrwkL
Only 1 day to go!
— MPN_Hub (@MPN_Hub) September 3, 2024
The MPN Hub will be covering #SOHO2024.
Sep 4–7
Houston, US, and online
We’ll be providing live social media coverage.
Keep an eye on our socials to see the latest updates! #mpnsm @SocietyofHemOnc pic.twitter.com/KDDX4YOmnw
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content